Substitute for form 1449A/PTO Complete if Known 10/594,162 Application Number INFORMATION DISCLOSURE STATEMENT BY APPLICANT Filing Date September 26, 2006 First Name Inventor Bartsch (Use several sheets if necessary) Group Art Unit **Examiner Name** Attorney Docket Number Sheet of 3 22393 **U.S. PATENT DOCUMENTS** U.S. Patent Document Examiner Cite Name of Patentee or Applicant of Date of Publication of Kind Code² Initials' No.1 Cited Document Cited document Number (if known) MM-DD-YYYY 6,110,924 Bosies, et. al. 08-29-2000 A1 6,242,455 06-05-2001 A2 Grams, et. al. FOREIGN PATENT DOCUMENTS Foreign Patent Document Date of Publication of Cite Name of Patentee or Cited Document Examiner Kind Code⁵ Office³ Number MM-DD-YYYY Applicant of Cited Document Initials' No.1 (if known) Boehringer Mannheim 12-30-1998 **B**1 WO 98/58915 **GMBH** KOSAK WO 00/40962 07-13-2000 B₂ B3 WO 01/25217 F. Hoffmann-La 04-12-2001 Roche AG F. Hoffmann-La B4 WO 02/089824 11-14-2002 Roche AG WO 97/23465 Boehringer Mannheim 07-03-1997 **B5 GMBH** WO 00/37109 **Euphar Group SRL** 06-29-2000 **B6** WO 2005/097058 Hoffmann-La Roche 10-20-2005 **B7** AG Tecnimede-Sociedade **B8** EP 1 018 340 07-12-2000 Technico-Medicinal

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this

01/02/2009

/Leigh Maier/


Examiner

Signature

Date Considered

form with next communication to applicant.

1 Unique citation designation number. See attached Kinds of U.S. Patent Documents. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation or abstract is attached.



NIONI DA	ATENT LITE	ים סוודי ג סי	DOCUMENTS

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title	T ²
Initials'	No.1		
		issue number(s), publisher, city and/or country where published	ļ
	C1	Egeblad, M., and Werb, Z., Nat. Rev. Cancer 2 (2002) 161-174;	
	C2	Overall, C.M., and Lopez-Otin, C., Nat. Rev. Cancer 2 (2002)	-
		657-672	ļ
	C3	Holmbeck, K., et al., Cell 99 (1999) 81-92	
	C4	Vu, T.H., et al., Cell 93 (1998) 411-422	
	C5	Shapiro, S.D., Curr. Opin. Cell Biol. 10 (1998) 602-608	
	C6	Lund, L.R., et al., EMBO J. 18 (1999) 4645-4656	
	C7	Carmeliet, P., et al., Nat. Genet. 17 (1997) 439-444	
	C8	Chang, C., and Werb, D., Trends Cell Biol. 11 (2001) S37-43	
	C9	Manes, S., et al., J. Biol. Chem. 274 (1999) 6935-6945	
	C10	Bergers, G., et al., Nat. Cell Biol. 2 (2000) 737-744	
	C11	Dong, Z., et al., Cell 88 (1997) 801-810	
	C12	Janowska-Wieczorek, A., et al., Blood 93 (1999) 3379-3390	
-	C13	Carstanjen, D., et al., Transfusion 42 (2002) 588-596	
	C14	Grams, F., et al., Biol. Chem. 382 (2001) 1277-1285	
	C15	Ansel, H., et. al., Pharmaceutical Dosage Forms and Drug	
		Delivery Systems, 6th ed., (1995), pp. 196 and 1456-1457	
	C16	Fabbri, L.M., and Hurd, S.S., Eur. Respir. J. 22 (2003) 1–2	
******	C17	Higuchi, T., and Connors, K.A., Advances in Analytical	
		Chemistry and Instrumentation 4 (1965) 117-212	
	C18	Yu, Z., and Westerlund, D., Chromatographia 44 (1997) 589-	<u> </u>
		594	
	C19	Hubert, Ph., et al., S. T. P. Pharma Pratiques 9 (1999) 160-180	
	C20	Souverain, S., et al., Journal of Chromatography B 801 (2004)	
		141-156)	
	C21	Chiap, P., et al., Journal of Chromatography B 817 (2005), 109-	
		117	
	C22	Hubert, P., et al., Analytica Chimica Acta 391 (1999) 135-148;	
·	C23	Hubert, Ph., et al., J. Pharm. Biomed. Anal. 36 (2004) 579-586	
	C24	Hamelmann, E., et al., Am. J Respir. Crit. Care Med. 156 (1997)	
	0.2.	766-775	
	C25	Cataldo, D.D., et al, Am. J. Pathol. 161 (2002) 491-498	
	C26	Aki, et. al. Jour of Pharm Sci, V. 90 (2001) 1186-1197	
	C27	Csabai, Int Jour of Pharm 91 (1993) 15-22	
	C28	Foley, Bio & Med Chem Ltr (2001) 969-972	\vdash
	C29	Kotzumi, 94 (1974) 1515	
	C30	Lopata, Jour of Phar Sci, 74 (1985) 211-213	
	1030	Lopaia, Jour of Friat Sci, 74 (1703) 211-213	Щ.

<u>a</u>	C31	Mura, Eur Jour of Pharm (2005) 99-106				
2 007 	C32	Piel, Jour of Pharm Sci, 86 (1997) 475-480				
	C33	Szejtli, Cyclodextrin T	Sech (1988) 186-307			
	C34	Iwaoku, Chem Pharm	Bull (1982) 1416-1421			
	C35	Loukas, Int Jour of Pha	arm 226 (2001) 207-211			
	C36	Suzuki, Chem Pharm Bull (1993) 1444-1447				
	C37	Lein, Oncogene (2002) 2089-2096				
	C38	Mura, Int Jour Pharm 260 (2003) 293-302				
			——————————————————————————————————————	·		
			•			
Examiner Signature	/Leiç	gh Maier/	DATE CONSIDERED	01/02/2009		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Unique citation designation number. Applicant is to place a check mark here if English language Translation or abstract is attached.

257509

date: 02/20/2007

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LM/